vs
Side-by-side financial comparison of Borr Drilling Ltd (BORR) and Guardant Health, Inc. (GH). Click either name above to swap in a different company.
Guardant Health, Inc. is the larger business by last-quarter revenue ($281.3M vs $267.7M, roughly 1.1× Borr Drilling Ltd). Borr Drilling Ltd runs the higher net margin — 13.1% vs -45.7%, a 58.8% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs -1.5%).
Borr Drilling Ltd is a global offshore drilling contractor owning and operating a modern fleet of high-spec jack-up rigs. It offers drilling services to oil and gas exploration and production firms, with main operations across the North Sea, Southeast Asia, Middle East, and West Africa for shallow-water and marginal field projects.
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
BORR vs GH — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $267.7M | $281.3M |
| Net Profit | $35.1M | $-128.5M |
| Gross Margin | — | 64.6% |
| Operating Margin | 36.0% | -43.0% |
| Net Margin | 13.1% | -45.7% |
| Revenue YoY | -1.5% | 39.4% |
| Net Profit YoY | 10.7% | -15.8% |
| EPS (diluted) | $0.14 | $-1.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $281.3M | ||
| Q3 25 | — | $265.2M | ||
| Q2 25 | $267.7M | $232.1M | ||
| Q1 25 | — | $203.5M | ||
| Q4 24 | — | $201.8M | ||
| Q3 24 | — | $191.5M | ||
| Q2 24 | $271.9M | $177.2M | ||
| Q1 24 | — | $168.5M |
| Q4 25 | — | $-128.5M | ||
| Q3 25 | — | $-92.7M | ||
| Q2 25 | $35.1M | $-99.9M | ||
| Q1 25 | — | $-95.2M | ||
| Q4 24 | — | $-111.0M | ||
| Q3 24 | — | $-107.8M | ||
| Q2 24 | $31.7M | $-102.6M | ||
| Q1 24 | — | $-115.0M |
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | 64.7% | ||
| Q2 25 | — | 65.0% | ||
| Q1 25 | — | 63.3% | ||
| Q4 24 | — | 61.6% | ||
| Q3 24 | — | 61.1% | ||
| Q2 24 | — | 59.1% | ||
| Q1 24 | — | 61.2% |
| Q4 25 | — | -43.0% | ||
| Q3 25 | — | -37.3% | ||
| Q2 25 | 36.0% | -45.9% | ||
| Q1 25 | — | -54.6% | ||
| Q4 24 | — | -62.4% | ||
| Q3 24 | — | -61.3% | ||
| Q2 24 | 38.4% | -56.8% | ||
| Q1 24 | — | -59.2% |
| Q4 25 | — | -45.7% | ||
| Q3 25 | — | -35.0% | ||
| Q2 25 | 13.1% | -43.0% | ||
| Q1 25 | — | -46.8% | ||
| Q4 24 | — | -55.0% | ||
| Q3 24 | — | -56.3% | ||
| Q2 24 | 11.7% | -57.9% | ||
| Q1 24 | — | -68.2% |
| Q4 25 | — | $-1.01 | ||
| Q3 25 | — | $-0.74 | ||
| Q2 25 | $0.14 | $-0.80 | ||
| Q1 25 | — | $-0.77 | ||
| Q4 24 | — | $-0.90 | ||
| Q3 24 | — | $-0.88 | ||
| Q2 24 | $0.12 | $-0.84 | ||
| Q1 24 | — | $-0.94 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $92.4M | $378.2M |
| Total DebtLower is stronger | — | $1.5B |
| Stockholders' EquityBook value | $1.0B | $-99.3M |
| Total Assets | $3.4B | $2.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $378.2M | ||
| Q3 25 | — | $580.0M | ||
| Q2 25 | $92.4M | $629.1M | ||
| Q1 25 | — | $698.6M | ||
| Q4 24 | — | $525.5M | ||
| Q3 24 | — | $585.0M | ||
| Q2 24 | $195.3M | $933.7M | ||
| Q1 24 | — | $1.0B |
| Q4 25 | — | $1.5B | ||
| Q3 25 | — | $1.1B | ||
| Q2 25 | — | $1.1B | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $-99.3M | ||
| Q3 25 | — | $-354.5M | ||
| Q2 25 | $1.0B | $-305.5M | ||
| Q1 25 | — | $-250.8M | ||
| Q4 24 | — | $-139.6M | ||
| Q3 24 | — | $-60.1M | ||
| Q2 24 | $999.2M | $-1.6M | ||
| Q1 24 | — | $68.3M |
| Q4 25 | — | $2.0B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | $3.4B | $1.3B | ||
| Q1 25 | — | $1.3B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | $3.2B | $1.6B | ||
| Q1 24 | — | $1.7B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $6.3M | $-26.4M |
| Free Cash FlowOCF − Capex | — | $-54.2M |
| FCF MarginFCF / Revenue | — | -19.3% |
| Capex IntensityCapex / Revenue | — | 9.9% |
| Cash ConversionOCF / Net Profit | 0.18× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-233.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-26.4M | ||
| Q3 25 | — | $-35.4M | ||
| Q2 25 | $6.3M | $-60.3M | ||
| Q1 25 | — | $-62.7M | ||
| Q4 24 | — | $-64.5M | ||
| Q3 24 | — | $-51.1M | ||
| Q2 24 | $16.0M | $-94.0M | ||
| Q1 24 | — | $-30.3M |
| Q4 25 | — | $-54.2M | ||
| Q3 25 | — | $-45.8M | ||
| Q2 25 | — | $-65.9M | ||
| Q1 25 | — | $-67.1M | ||
| Q4 24 | — | $-83.4M | ||
| Q3 24 | — | $-55.3M | ||
| Q2 24 | — | $-99.1M | ||
| Q1 24 | — | $-37.2M |
| Q4 25 | — | -19.3% | ||
| Q3 25 | — | -17.3% | ||
| Q2 25 | — | -28.4% | ||
| Q1 25 | — | -33.0% | ||
| Q4 24 | — | -41.3% | ||
| Q3 24 | — | -28.9% | ||
| Q2 24 | — | -55.9% | ||
| Q1 24 | — | -22.1% |
| Q4 25 | — | 9.9% | ||
| Q3 25 | — | 3.9% | ||
| Q2 25 | — | 2.4% | ||
| Q1 25 | — | 2.2% | ||
| Q4 24 | — | 9.4% | ||
| Q3 24 | — | 2.2% | ||
| Q2 24 | — | 2.9% | ||
| Q1 24 | — | 4.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.18× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.50× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BORR
| Transferred Over Time | $256.6M | 96% |
| Transferred At Point In Time | $11.1M | 4% |
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
